1. Home
  2. CTKB vs ANAB Comparison

CTKB vs ANAB Comparison

Compare CTKB & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTKB
  • ANAB
  • Stock Information
  • Founded
  • CTKB 1990
  • ANAB 2005
  • Country
  • CTKB United States
  • ANAB United States
  • Employees
  • CTKB N/A
  • ANAB N/A
  • Industry
  • CTKB Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • ANAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • CTKB Health Care
  • ANAB Health Care
  • Exchange
  • CTKB Nasdaq
  • ANAB Nasdaq
  • Market Cap
  • CTKB 718.8M
  • ANAB 759.5M
  • IPO Year
  • CTKB 2021
  • ANAB 2017
  • Fundamental
  • Price
  • CTKB $5.12
  • ANAB $18.59
  • Analyst Decision
  • CTKB Strong Buy
  • ANAB Buy
  • Analyst Count
  • CTKB 2
  • ANAB 12
  • Target Price
  • CTKB $9.25
  • ANAB $41.20
  • AVG Volume (30 Days)
  • CTKB 747.0K
  • ANAB 1.4M
  • Earning Date
  • CTKB 02-27-2025
  • ANAB 03-10-2025
  • Dividend Yield
  • CTKB N/A
  • ANAB N/A
  • EPS Growth
  • CTKB N/A
  • ANAB N/A
  • EPS
  • CTKB N/A
  • ANAB N/A
  • Revenue
  • CTKB $201,210,000.00
  • ANAB $57,172,000.00
  • Revenue This Year
  • CTKB $7.26
  • ANAB $229.13
  • Revenue Next Year
  • CTKB $8.20
  • ANAB N/A
  • P/E Ratio
  • CTKB N/A
  • ANAB N/A
  • Revenue Growth
  • CTKB 9.88
  • ANAB 282.17
  • 52 Week Low
  • CTKB $4.66
  • ANAB $12.21
  • 52 Week High
  • CTKB $9.33
  • ANAB $41.31
  • Technical
  • Relative Strength Index (RSI)
  • CTKB 37.48
  • ANAB 55.28
  • Support Level
  • CTKB $5.18
  • ANAB $12.21
  • Resistance Level
  • CTKB $5.48
  • ANAB $21.57
  • Average True Range (ATR)
  • CTKB 0.27
  • ANAB 1.72
  • MACD
  • CTKB 0.01
  • ANAB 0.39
  • Stochastic Oscillator
  • CTKB 27.85
  • ANAB 68.16

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: